High PD-1 expression and suppressed cytokine signaling distinguish T cells infiltrating follicular lymphoma tumors from peripheral T cells
June H. Myklebust(Oslo University Hospital), Ronald Levy(Hôpital Necker-Enfants Malades), Joshua Brody(New York University), Roch Houot(Inserm), Jonathan M. Irish(Vanderbilt University), Michael R. Green(Harvard University), John M. Timmerman(Sheba Medical Center), Jan Delabie, Jonathan Said(University of California, Los Angeles), Arne Kolstad(Oslo University Hospital), Holbrook E. Kohrt(Stanford University), Debra K. Czerwinski(Stanford University), Ash A. Alizadeh(California Institute for Regenerative Medicine)
Cited by 154
Related Papers
Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling
|Nature|2000|10k
Axicabtagene Ciloleucel CAR T-Cell Therapy in Refractory Large B-Cell Lymphoma
|New England Journal of Medicine|2017|6k
The Use of Molecular Profiling to Predict Survival after Chemotherapy for Diffuse Large-B-Cell Lymphoma
|New England Journal of Medicine|2002|3.9k
Long-term safety and activity of axicabtagene ciloleucel in refractory large B-cell lymphoma (ZUMA-1): a single-arm, multicentre, phase 1–2 trial
|The Lancet Oncology|2018|2.3k
Genetics and Pathogenesis of Diffuse Large B-Cell Lymphoma
|New England Journal of Medicine|2018|2.3k